3728 Jinke Rd, Building 1, West Wing, Shanghai, China
info@tyligand.com
Tyligand Bioscience was recognized in the first KPMG China 2021 Biotechnology Innovation 50 Enterprises
On June 15, 2022, the internationally renowned consulting firm KPMG released the "First KPMG China Biotechnology Innovation 50 Enterprises". With its achievements and future development potential in the field of small molecule drug innovation, Tyligand Bioscience was nominated for the list.
KPMG's selection activity covers six major unlisted companies in biopharmaceuticals, cell therapy, gene therapy, companion diagnostics, medical devices, and clinical research, from the perspective of technology and product line leadership, core management team and R&D team background The participating companies will be evaluated on 5 main core dimensions, including capital market activity, product pipeline richness, and financial health. The selection of KPMG China's Biotechnology Innovation 50 Enterprises demonstrates the recognition and encouragement of the industry and professional institutions for Tyrena's innovation capabilities and future development.
Since its establishment, Tyligand has always focused on patient accessibility and independently innovated for the global market. So far, the company has established a rich product portfolio of preclinical and clinical stage projects through completely independent research and development, as well as the world's first dual-function immune agonist (DATIA®) research and development platform and innovative payload platform of antibody-drug conjugate ADC.
Dr. Tony Zhang, co-founder and CEO of Tyligand, said:
"Thanks to KPMG China for the nomination and the recognition of investors, as well as the support of many partners. Tyligand is based on the design and synthesis capabilities of complex small molecules, combined with cutting-edge biological progress and technical advantages such as AI, focusing on non-significant connections in cross-fields , to improve the quality, speed, and success rate of R&D innovation. The dual-function immune agonist (DATIA®), pioneered by Tyligand’s team, first induces tumor cells to produce immune factors, and then induces their apoptosis to help the establishment of the adaptive immune system And achieve the ultimate goal of eradicating tumors. This will provide a different way of thinking and approach to conquer cancer. We will use the DATIA® platform to strengthen external cooperation, expand the speed and dimension of its application, and develop more clinically proven molecular."
Tyligand Bioscience is a clinical-stage biotech company founded in 2017, focusing on the discovery and development of innovative cancer therapeutics. The company commenced business operations in 2018. Leveraging decades of profound experience in leading drug discovery and development at multinational pharmaceutical companies, the management team has successfully established technology platforms with fully integrated capabilities across small molecules and antibody-drug conjugates (ADCs). Serving as an innovation engine, these platforms have enabled the company to build a diversified pipeline encompassing multiple drug candidates.
Consistently driven by the mission to address significant unmet clinical needs, Tyligand Bioscience is dedicated to becoming a leading global biopharmaceutical enterprise. By continuously delivering high-quality, differentiated innovative therapies, the company aims to improve the quality of life for patients worldwide and create long-term commercial value.
For more info about Tyligand Bioscience, please visit www.tyligand.com
- Tyligand Bioscience